ISC High Performance 2022: Liqid Introduces EMEA Attendees to Composable Disaggregated Infrastructure for a More Flexible, Sustainable Data Center
30.5.2022 09:30:00 EEST | Business Wire | Press release
Liqid, the world’s leading software company delivering data center composability, announced today it is taking part in ISC High Performance 2022 (booth #B211), providing live demonstrations of the company’s Liqid Matrix™ composable disaggregated infrastructure (CDI) software. Dynamic infrastructure orchestration from Liqid delivers improved IT performance and agility for the most demanding next-gen applications such as artificial intelligence and machine learning (AI+ML), edge computing deployments, high-performance computing, and virtualization. Increased efficiency helps minimize the data center footprint, delivering software-defined ability to share resources no matter where they physically reside, making Liqid solutions fundamental to a more sustainable data center ecosystem. Available today for customers in the Europe, Middle East, & Africa (EMEA) region, solutions based on Liqid Matrix CDI software deliver architectural flexibility and efficiency to maximize time-to-value for high-value applications across industry verticals.
“AI applications, edge data center deployments reading multiple streams of sensor data, HPC-driven genomic research, and even more traditional software deployments like virtualization are taxing traditional data center infrastructures, increasingly making them neither practical nor sustainable,” said Paul Silver, Vice President and General Manager, EMEA, Liqid. “We’re excited to be able to bring our composable solutions to ISC High Performance attendees and the wider EMEA market to help better address the sea changes taking place in the data center ecosystems.”
Liqid Matrix software enables IT users to configure bare-metal servers in seconds. With Liqid Matrix, independent resource pools are orchestrated on-demand to instantly address the requirements of the specific workload. Once the workload is complete, resources are released back into the pool for use by other applications. This eliminates the need for costly overprovisioning of infrastructure, reduces power and cooling requirements, and enables the most efficient and sustainable data center architectures.
Liqid offers EMEA customers a cost-effective way to disaggregate and pool data center resources at large scale via software, across all industry-standard fabrics, for dynamically configurable, bare-metal servers. With composable disaggregated infrastructure solutions from Liqid, IT users can:
- Accelerate Time-to-Value: Dynamically configure servers in seconds to meet exacting workload requirements. Create configurations that aggregate the power of dozens of GPUs and other accelerators as required.
- Improve IT Agility: Scale resources like compute, networking, NVMe storage, GPU, FPGA, and storage-class memory beyond a server’s physical limitations, across all industry-standard fabrics, with just a couple of clicks; when data center devices are no longer needed, they are released back to the pool to be used by other applications. Leverage Liqid Command Center’s RESTful API and integrations with popular tools like Ansible to automate the provisioning of bare‐metal resources.
- Increase Efficiency: Only purchase resources when they’re needed. Extend the life cycle of existing IT server investments. Better manage costs associated with data center footprint with greater infrastructure utilization.
“Liqid is a company that offers a flexible, software-defined infrastructure designed to optimize the access and usage of high-value IT components. Liqid has worked to create what it called ‘composable disaggregated infrastructure’ that frees IT users from vendor lock-in and traditional purchasing cycles, enabling them to build a living data center architecture that changes to meet their business needs and scales as required,” wrote senior analyst Scott Sinclair and senior research analyst Moya Keane of Enterprise Strategy Group (ESG), a division of TechTarget, in a recent ESG Showcase. “A composable infrastructure provides significant improvements to performance, architectural optimization, hardware utilization issues, and, importantly, footprint efficiency—basically eliminating the urge to overprovision.”
To download ESG’s “Why IT Must Prioritize Sustainability,” go here. Schedule an appointment with an expert on solutions based on Liqid Matrix CDI software and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.
About Liqid
Liqid’s composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005033/en/
Contact information
Robert Brumfield
Sr. Director, Global Communications
Liqid
917 224 7769
brumfield.bob@liqid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
